Valneva SE revenue breakdown overview

Valneva SE revenue for the last year amounted to 183.63 M USD, the most of which — 183.43 M USD — came from its highest performing source at the moment, Development and Commercialization of Prophylactic Vaccines, the year earlier bringing 166.18 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Valneva SE 52.56 M USD, and the year before that — 35.64 M USD.